Drugs / AZD-8797
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06087289 | Apr 2023 → Apr 2025 | fallopian tube cancer, ovarian epithelial tumor, peritoneum cancer | Novakand Pharma AB | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06012565 | Oct 2020 → Aug 2021 | COVID-19 | Novakand Pharma AB | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06030375 Comparator | Feb → Apr 2020 | — | Novakand Pharma AB | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD-8797 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2349310 ↗ |
| Known as | KAND567 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06030375 ↗ |
| Modality | Small molecule | — CHEMBL2349310 ↗ |
| Route | Oral | “2 x 125 mg capsules for oral administration.” NCT06012565 ↗ |